Puma Biotech NYSE:PBYI Securities Lawsuit

- by

Company: Puma Biotech
Ticker Symbol: NYSE:PBYI
Class Period: Jul-23-14 to May-13-15
Date Filed: Jun-8-15
Lead Plaintiff Deadline: Aug-7-15
Court: Central District of California
San Francisco, CA: A federal securities class action lawsuit filed against Puma Biotech and certain executives. A complaint has been filed in the Central District of California on behalf of investors who purchased Puma Biotech securities between July 23, 2014 and May 13, 2015, inclusive (the "Class Period").

The action alleges that the Company and its executives violated federal securities laws during the Class Period by failing to disclose that (1) the Company' New Drug Application (NDA) filing for neratinib would be purposed toward a positive early stage breast cancer indication as opposed to the previously announced metastatic breast cancer; (2) the Company will need to submit additional safety data from preclinical carcinogenicity studies with its NDA filing, which the Company does not possess; (3) the required additional studies would push the timeline for filing the NDA into at least the first quarter of 2016; and (4) the Company overstated results from its Phase III ExteNET Trial. Puma Biotechnology, Inc. (NYSE:PBYI) has 32.15 million outstanding shares with market capitalization of 4.46 Billion and its share price finished at $138.79 by plunging -3.78% in last traded session. As the returns are concern, return on equity was recorded -95.70% .

If you acquired the securities of the defendants during the Class Period you may, no later than the Lead Plaintiff Deadline shown above, request that the Court appoint you as lead plaintiff through counsel of your choice. You may also choose to remain an absent class member. A lead plaintiff must meet certain requirements.

Puma Biotech NYSE:PBYI Securities Fraud Legal Help

If you have suffered from financial losses, you may qualify for damages or remedies that may be awarded in a possible Puma Biotech securities class action lawsuit. Please click the link below to submit your complaint for a free evaluation.

Maybe it's your stockbroker

Add Your Comment on This Issue

Fields marked * are mandatory. Please read our comment guidelines before posting.


Note: Your name will be published with your comment.

*Email Address:

Your email will only be used if a response is needed.

*Your Comment:
Request Legal Help